DLBCL has an aggressive and heterogeneous biological course, showing variable response to most commonly used chemotherapy protocols in patients with the same tumor stage and sub-stage. 7 Several prognostic factors have been identified in canine lymphoma 6, 7, 9 ; however, only 2 studies have specifically analyzed prognostic factors in DLBCL, to our knowledge. 2, 8 Cell proliferation has been studied in different tumors, and several markers have been described in veterinary medicine. 6 Ki67 is a protein expressed at every phase of the cell cycle, except at G0, with greater expression during mitosis (M). 9 Ki67 is an important marker of cell proliferation for predicting the prognosis of DLBCL in humans. 9 
MIB-1 is the monoclonal antibody most used to analyze
Ki67 immunoexpression in some types of aggressive lymphomas. In veterinary medicine, the role of Ki67 as a prognostic factor in high-grade B-cell lymphomas has been demonstrated by flow cytometry 11 ; results in paraffinembedded tissues are still being debated. 6, 18 As with Ki67, the mitotic index (MI) is an indicator of cell proliferation and used as a prognostic factor in human patients diagnosed with non-Hodgkin lymphoma. 1 Although some studies suggested that MI is not a good prognostic factor in canine lymphoma, 3, 6 other studies have found a significant correlation between shorter survival time and MI.
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743280V DIXXX10.1177/1040638717743280Ki67 prognostic value in diffuse large B-cell lymphomaSierra Matiz et al. We analyzed cell proliferation markers Ki67 and MI in dogs diagnosed with DLBCL to determine if a correlation existed between these markers and patient prognosis. Cases were selected from dogs with lymphoma admitted to veterinary centers in the state of Sao Paulo from January 2009 to September 2015. Cases were eligible for inclusion in this study if they met the following criteria: 1) histologic diagnosis of DLBCL examined by a single pathologist (FA Sueiro) and classified according to the WHO classification, 16 and 2) lack of previous chemotherapy treatment (including prednisone), and treatment using the 19-wk CHOP based protocol (cyclophosphamide, doxorubicin, vincristine and prednisone) recommended by the University of WisconsinMadison. 15 Clinical and epidemiologic data on the patients such as breed, weight, sex, clinical signs, and survival time were obtained from the patient's medical record. Clinical staging was established through physical examination, hemogram, basic serum biochemistry (creatinine and alanine aminotransferase), abdominal ultrasound, and thorax radiography in 3 projections. Bone marrow aspiration was only performed in patients with evidence of atypical lymphocytes in peripheral blood, lymphocytosis, or pancytopenia detected on initial hemogram. Sub-stages were classified as "a" when there were no clinical signs and "b" when the patient had clinical signs including gastrointestinal signs, respiratory signs, fever, depression, or lethargy. Survival time was considered from the date of diagnosis to the day of death or the date of last check-up at our hospital. All samples were analyzed by the same pathologist, and immunophenotyping was performed by immunohistochemistry, which used CD3 and CD79a antibodies to identify T-and B-lymphocytes, respectively. When CHOP chemotherapy was no longer effective at controlling remission, CCNU (lomustine) was implemented as first rescue protocol.
For Ki67 immunostaining, 3-μm sections were cut from paraffin-embedded samples and mounted on silane-coated glass slides (Starfrost, Knittel Glass, Braunschweig, Germany). The slides were de-waxed and hydrated, and sections were subjected to antigen retrieval with citrate buffer (pH 6) in a Pascal pressure chamber (Dako North America, Carpinteria, CA). Endogenous peroxide blocking was carried out using blocking solution (Spring Biosciences, Pleasanton, CA) according to the manufacturer's recommendation. Blocking of nonspecific reactions was performed with protein block (Novocastra, Newcastle, UK), and sections were incubated with the primary antibody (monoclonal mouse MIB-1, Dako; 1:100) for 2 h at room temperature of 27°C. HistoFine (Nichirei Biosciences, Tokyo, Japan) was used as secondary antibody, and sections were stained with 3,3'diaminobenzidine (DAB Novolink, Leica Biosystems, Newcastle, UK). Samples were counterstained with Harris hematoxylin (Easypath, São Paulo, Brazil). A sample of canine lymphoma known to be positive to MIB-1 was used as the positive control. A negative control was obtained by replacing the primary antibody with the dilution solution.
For Ki67 evaluation, a single pathologist (FA Sueiro) selected areas with the highest proportion of immunopositive neoplastic lymphocytes at 100× magnification and manually counted the number of positively stained cells in 1 cm 2 using a 10 × 10 mm grid reticle in a light microscope (Eclipse E200, Nikon, Japan) at 400× magnification. 17 Five high power fields (HPF) were analyzed to calculate the mean number of positive cells for each case. For MI, the pathologist selected areas with the highest overall mitotic activity and counted the total mitotic figures present in 10 HPF (400×) as described previously. 13 The cutoff points established for the mean numbers of Ki67-positive cells was 107, and the cutoff point for total MI was 21. Ki67 and MI values above or below the cutoff points were classified into "high" or "low" groups, respectively.
For statistical purposes, the Shapiro-Wilk test was used to assess normality of distribution of the continuous variables, and survival time curves were estimated and compared between the "high" and "low" groups of each marker by the Kaplan-Meier method and log-rank test. The degree of correlation between Ki67 and MI was estimated by Spearman correlation coefficient. The Fisher exact test was used to analyze potential associations between the markers and clinical stage (stages III or IV and sub-stages "a" or "b"). Significance was considered at p < 0.05.
The dog breeds most commonly diagnosed with DLBCL were mixed-breed dogs (n = 6), followed by Rottweilers (n = 5). Average age was 8.4 y (range: 4-14), with 18 females (12 intact and 6 spayed) and 11 males (8 intact and 3 castrated). Clinical staging classified 6 patients as stage III (generalized lymph node involvement), 22 as stage IV (liver or spleen involvement ± stage III), and 1 as stage V (blood or bone marrow involvement and/or other organ involvement ± any stage). Most dogs showed no clinical signs of the disease, with 18 patients being classified as sub-stage "a" and 11 as sub-stage "b" (Table 1) .
Studies on dogs with DLBCL have reported that mixedbreed dogs are the most commonly affected, 5, 8 as observed in our study in which they corresponded to 21% of patients. Rottweiler was the second most affected breed in our study with 17% of the total DLBCL cases. A 2015 study analyzed 51 dogs with DLBCL and observed that Rottweilers also corresponded to the second most affected breed (9.8%). 8 However, studies have not yet evaluated a significant number of animals that would confirm a breed predisposition.
The median survival time of the patients in our study was 245 d, similarly to previous studies on DLBCL. 16 Thirteen dogs died as a result of the disease before the end of the treatment protocol. Interestingly, 80% of Rottweiler (4 of 5) and 100% of mixed-breed patients (6 of 6) were in remission throughout the treatment.
The age of onset is similar to those reported in the literature, where DLBCL is more frequent in animals aged 7.5-8 y. 5, 8 The majority of patients in our study were classified as stage IV (76%) and did not show clinical signs of the disease (sub-stage "a", 64%), in agreement with previous findings.
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Ki67 staining was restricted to the nucleus (Fig. 1) and was positive in all samples. The mean value of Ki67 was 107 (range: 1-446) and 21 for MI (range: 0-73). Based on the mean value for Ki67, we evaluated 2 groups: Ki67-low (<107, n = 21) and Ki67-high (≥107, n = 8). The median survival time for Ki67-low (294 d) was significantly longer (p < 0.05) than for Ki67-high dogs (63 d; Table 2 ). Based on the mean MI, we also identified 2 groups: MI-low (<21, n = 17) and MI-high (≥21, n = 12). No statistically significant difference was detected in the median survival time between groups MI-low (294 d) and MI-high (129 d; Fig. 2) . A statistically significant relationship was not observed between Ki67 and MI values, or between either factor and stages or sub-stages (p > 0.05).
Ki67 and MI have been considered prognostic factors in dogs with mast cell tumor and melanoma. 13, 14, 17 In the 2 most recent reports discussing prognosis of dogs with DLBCL, 2, 8 no relationship was found between Bcl2 and MYC immunoexpression and prognosis, 2 whereas the other study reported that a lymphocyte-to-monocyte ratio <1.2 (flow cytometry) is a prognostic factor in dogs with highgrade B-cell lymphomas. 8 Similarly, other authors quantified Ki67 by flow cytometry and established it to be a prognostic factor in dogs with B-cell lymphomas. 11 This result is consistent with our study, which demonstrated that a correlation exists between Ki67 immunostaining and shorter survival times in dogs with DLBCL. Interestingly, the former study, 11 did not allow for a cutoff point to be determined given the lack of significant difference when the survival time between groups was compared with values above and below the median. A significant association or correlation was reported when Ki67 values were calculated by percentile, which enabled 3 groups to be established (low, intermediate, and high) with correlation between the intermediate group and shorter survival times. 11 We also compared survival times from cases with central values of Ki67 immunoexpression with those of extreme values and found no association (data not shown). Although the statistical analysis in the previous study 11 differs from our study, the results suggest that Ki67-low is a good prognostic marker in dogs with B-cell lymphoma, especially DLBCL.
Our results partially contradict others that concluded that a higher number of Ki67 cells was associated with a better response to chemotherapy in multicentric lymphoma and therefore a longer disease-free interval with no difference found in overall survival time. 10 However, one of those studies evaluated random areas instead of areas of highest Ki67 immunoexpression for counting. 10 Another study observed no significant correlation between survival time and the number of Ki67-positive cells. 6 It is important to note that the counting technique used in our study was different than the one reported in these other studies.
The cutoff point established for MI was not a prognostic factor in dogs with DLBCL in our study. This result is in disagreement with others who determined the same MI value (21) and observed shorter survival time in 26 dogs with MI >21, comparing them to 353 dogs with MI <20 with multicentric lymphoma. 16 However, that publication did not differentiate DLBCL from other histologic types such as indolent lymphomas and other low-grade lymphomas, which resulted in a heterogeneous group that may have affected findings.
Our study has limitations such as its retrospective nature and the relatively small number of cases. A lack of homogeneity of clinical stages, especially in stage V, may contribute to the lack of association found between clinical staging and cell proliferation.
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